This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 Top Large-Cap Stocks Set to Soar on Earnings Next Week
by Nalak Das
In line with improving earnings results, six large-cap stocks are poised to beat earnings estimates next week.
The Zacks Analyst Blog Highlights: Alphabet, salesforce.com, L3Harris, McKesson and Synopsys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, salesforce.com, L3Harris, McKesson and Synopsys
Is McKesson (MCK) a Profitable Stock for Value Investors?
by Zacks Equity Research
McKesson (MCK) is a good value-oriented pick for investors from all angles.
Buy 6 Top-Ranked Surging S&P 500 Stocks to Gain More in 2020
by Nalak Das
Several large-cap stocks within the index have already popped more than 10% year to date and still have strong upside left.
Will McKesson Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in McKesson.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF
by Sanghamitra Saha
The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.
10 Top-Ranked S&P 500 Stocks Outperforming in 2020
by Sweta Killa
The rally has been broad based and there are winners across various corners of the space.
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Estee Lauder, Bank of New York ??? Mellon, Canadian Pacific Railway, McKesson and Ameriprise Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Estee Lauder, Bank of New York ??? Mellon, Canadian Pacific Railway, McKesson and Ameriprise Financial
Top Stock Reports for Estee Lauder, BNY Mellon & Canadian Pacific Railway
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Estee Lauder (EL), Bank of New York Mellon (BK) and Canadian Pacific Railway (CP).
MCK vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
McKesson, Walgreens Form JV for European Pharmaceutical Unit
by Zacks Equity Research
The VA selects McKesson (MCK) as their prime pharmaceutical supplier.
SaMD Drives All Facets of US Healthcare: 3 Stocks to Watch
by Sreyoshi Mukherjee
As IoT slowly takes over the healthcare fraternity, let's take a look at three stocks which might prove to be profitable investment options over the long run.
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
McKesson (MCK) Q2 Earnings Meet Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.00% and 4.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Oct 30 Earnings Roster: MCK, MASI & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) registers growth at CER across its key operating segments in Q1.
Integra LifeSciences' (IART) Earnings Top Estimates in Q3
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.
New Strong Buy Stocks for October 25th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday:
Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.